Literature DB >> 11431007

Role of poly(ADP-ribose) synthetase activation in the development of experimental allergic encephalomyelitis.

G S Scott1, P Hake, R B Kean, L Virág, C Szabó, D C Hooper.   

Abstract

Peroxynitrite formation has been demonstrated during experimental allergic encephalomyelitis (EAE). Furthermore, peroxynitrite has been identified as an activator of poly(ADP-ribose) synthetase (PARS), an enzyme implicated in neurotoxicity. In the current study, we examined the role of PARS activation in the development of EAE. Administration of the PARS inhibitor 5-iodo-6-amino-1,2-benzopyrone (INH2BP) delayed the onset of EAE and reduced the incidence and severity of disease signs. Moreover, drug treatment lowered iNOS activity and decreased cell infiltration in cervical spinal tissues from EAE-sensitized animals. To conclude, the results of the present investigation suggest that PARS activity may contribute to the pathogenesis of EAE.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11431007     DOI: 10.1016/s0165-5728(01)00329-0

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  12 in total

1.  Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats.

Authors:  Alberto Chiarugi
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

2.  Long-term suppression of EAE relapses by pharmacological impairment of epitope spreading.

Authors:  L Cavone; B Peruzzi; R Caporale; A Chiarugi
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

3.  PARP-1 controls NK cell recruitment to the site of viral infection.

Authors:  Qiyang Shou; Huiying Fu; Xiaopei Huang; Yiping Yang
Journal:  JCI Insight       Date:  2019-06-20

Review 4.  The importance of NAD in multiple sclerosis.

Authors:  W Todd Penberthy; Ikuo Tsunoda
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 5.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

6.  Early blood-brain barrier permeability in cerebella of PLSJL mice immunized with myelin basic protein.

Authors:  Sergei Spitsin; Carla Portocarrero; Timothy W Phares; Rhonda B Kean; Christine M Brimer; Hilary Koprowski; D Craig Hooper
Journal:  J Neuroimmunol       Date:  2008-04-11       Impact factor: 3.478

7.  Activation of poly(ADP-ribose) polymerase-1 delays wound healing by regulating keratinocyte migration and production of inflammatory mediators.

Authors:  Tarek El-Hamoly; Csaba Hegedűs; Petra Lakatos; Katalin Kovács; Péter Bai; Mona A El-Ghazaly; Ezzeddin S El-Denshary; Éva Szabó; László Virág
Journal:  Mol Med       Date:  2014-08-26       Impact factor: 6.354

Review 8.  The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host Interactions.

Authors:  Máté A Demény; László Virág
Journal:  Cancers (Basel)       Date:  2021-04-24       Impact factor: 6.639

9.  PARP-1 inhibitor, DPQ, attenuates LPS-induced acute lung injury through inhibiting NF-κB-mediated inflammatory response.

Authors:  Gang Wang; Xiaojia Huang; Yongjin Li; Kangkang Guo; Pengbo Ning; Yanming Zhang
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

10.  Novel insights into the neuroendocrine control of inflammation: the role of GR and PARP1.

Authors:  Fernando Aprile-Garcia; María Antunica-Noguerol; Maia Ludmila Budziñski; Ana C Liberman; Eduardo Arzt
Journal:  Endocr Connect       Date:  2013-12-19       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.